Moderna (MRNA) Enters MOU to Supply up to 110M COVID-19 Vaccine Doses to the African Union

Moderna (MRNA) Announces EMA's CHMP Recommends Booster Dose of its COVID-19 Vaccine in the European Union

October 25, 2021 4:53 PM EDT

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has concluded that a booster dose of Spikevax, the Companys vaccine against COVID-19, at the 50... More

Moderna says its COVID-19 vaccine protective, safe in young children

October 25, 2021 8:44 AM EDT

By Manas Mishra

(Reuters) -Moderna Inc said on Monday its COVID-19 vaccine generated a strong immune response in children aged six to 11 years and that it plans to submit the data to global regulators soon.

Moderna said its two-dose vaccine generated virus-neutralizing antibodies in children and safety was comparable to what was previously seen in clinical trials of adolescents and adults. It cited interim data that has yet to be peer reviewed.

It was unclear when U.S. regulators will weigh in on the shot. The Moderna COVID-19 vaccine is authorized for adults over... More

Moderna (MRNA) Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age

October 25, 2021 8:31 AM EDT

Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced positive interim data from the Phase 2/3 study, called the KidCOVE study, of mRNA-1273, the Companys vaccine candidate against COVID-19, in children 6 to under 12 years of age. This interim... More

Moderna (MRNA) Stock Plunges as Deutsche Bank Starts at Sell on Valuation, Sees 25% Downside

October 22, 2021 10:16 AM EDT

Deutsche Bank analyst Emmanuel Papadakis initiated the research coverage of Moderna (NASDAQ: MRNA) at Sell with a price target of $250.00 per share, signaling a potential downside of around 25%.

Despite the Sell rating, Papadakis praises MRNAs execution and the strategic discipline that has yielded massive returns in the past 12-18 months. However, the valuation at the moment is very high (+185% YTD).

We concur there is potential to disrupt dynamics in the broader viral infectious... More

Pre-Open Stock Movers 10/22: (PHUN) (DWAC) (MAT) Higher; (MTCR) (SNAP) (INTC) Lower (more...)

October 22, 2021 9:20 AM EDT

Pre-Open Stock Movers:

Phunware, Inc. (NASDAQ: PHUN) 366% HIGHER; continues to see upside on meme stock impact

Digital World Acquisition Corp. (NASDAQ: DWAC) 89% HIGHER; the Donald Trump SPAC continues higher after jumping 357% intra-day.

Metacrine, Inc. (NASDAQ: MTCR) 53% LOWER; reported interim results from a Phase 2a clinical trial evaluating the efficacy and safety of MET642, a farnesoid X receptor (FXR) agonist, in approximately 60 non-alcoholic steatohepatitis... More

CDC Advisory Committee Recommends Booster Shot of Moderna's (MRNA) COVID-19 Vaccine

October 22, 2021 5:40 AM EDT

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. Centers for... More

Deutsche Bank Starts Moderna (MRNA) at Sell

October 22, 2021 4:04 AM EDT

(Updated - October 22, 2021 6:06 AM EDT)

Deutsche Bank analyst Emmanuel Papadakis initiates coverage on Moderna (NASDAQ: MRNA) with a Sell rating and a price target of $250.00.

The analyst comments "Moderna is a concept company that has ridden a wave of disruptive innovation, pandemic serendipity and management vision (plus a little public funding) to become a concept stock. Whilst execution has not been lacking, the strategic discipline to stay focused on mRNA is a virtue... More